Stockscreener 앱 받기
22.03
5.05%
1.06
시간 외 거래:
22.47
0.44
+2.00%
Oculis Holding Ag 주식(OCS)의 최신 뉴스
Oculis gains on FDA breakthrough therapy status for optic neuritis therapy - MSN
Can Oculis Holding AG Equity Warrant stock beat analyst upgradesJuly 2025 Spike Watch & Reliable Breakout Forecasts - ulpravda.ru
IPO Launch: Why Oculis Holding AG stock is recommended by analystsWeekly Profit Report & Free Reliable Trade Execution Plans - ulpravda.ru
Can Oculis Holding AG (CR5) stock surprise with quarterly resultsMarket Movement Recap & Long-Term Capital Growth Ideas - ulpravda.ru
Why Oculis Holding AG Equity Warrant stock attracts global investorsCandlestick Trading Patterns & Low Risk Trading Plans - bollywoodhelpline.com
Weekly Earnings: Can Oculis Holding AG Equity Warrant stock beat analyst upgradesQuarterly Investment Review & Comprehensive Market Scan Reports - ulpravda.ru
Why Oculis Holding AG stock could benefit from AI revolutionJuly 2025 Snapshot & Comprehensive Market Scan Reports - ulpravda.ru
Will Oculis Holding AG Equity Warrant stock deliver consistent dividendsJuly 2025 Update & Long-Term Safe Investment Ideas - ulpravda.ru
Why Oculis Holding AG stock is recommended by analysts2025 Price Momentum & Low Risk High Reward Ideas - ulpravda.ru
Will Oculis Holding AG stock maintain momentum in 2025Buy Signal & AI Driven Stock Reports - ulpravda.ru
Why Oculis Holding AG Equity Warrant stock could rally in 2025 - ulpravda.ru
OCSOculis Holding Latest Stock News & Market Updates - Stock Titan
Oculis Holding Ag Announces the Transformative Potential of Its Late-Stage Pipeline - MarketScreener
Is Oculis Holding AG Equity Warrant stock positioned well for digital economyFibonacci Retracement Levels & Unlock Smart Investment Tactics That Work - ulpravda.ru
Oculis Holding AG Advances PIONEER Program with Breakthrough Therapy Designation for Privosegtor and Prepares for Upcoming J.P. Morgan Healthcare Conference Presentation - Quiver Quantitative
Experimental eye drugs target vision loss in diabetes and optic nerve disease - Stock Titan
FDA grants Breakthrough Therapy Designation to Oculis' privosegtor for optic neuritis - Eyes On Eyecare
Should I hold or sell Oculis Holding AG Equity Warrant stock in 20252026 world cup usa national team qualification goalkeepers transition play odds analysis insights - ulpravda.ru
How Oculis Holding AG Equity Warrant stock benefits from tech adoption2026 world cup usa national team qualification star players transition play knockout prediction guide - ulpravda.ru
What drives Oculis Holding AG stock priceDouble Top/Bottom Patterns & Free Stay Ahead With Picks - earlytimes.in
Oculis (NASDAQ:OCS) Shares Gap UpShould You Buy? - MarketBeat
Oculis gains on FDA breakthrough therapy status (OCS:NASDAQ) - Seeking Alpha
Oculis stock surges after FDA grants breakthrough therapy designation By Investing.com - Investing.com Nigeria
Oculis stock surges after FDA grants breakthrough therapy designation - Investing.com
Aug Rallies: Can Oculis Holding AG CR5 stock surprise with quarterly resultsEarnings Beat & Reliable Breakout Forecasts - moha.gov.vn
Oculis Holding AG Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis - MarketScreener
Oculis Holding Says FDA Granted Breakthrough Therapy Designation for Privosegtor - marketscreener.com
Oculis Holding AG's Privosegtor Receives Breakthrough Therapy Designation for Optic Neuritis Treatment - Quiver Quantitative
Oculis tilkynnir um að Matvæla- og lyfjastofnun - GlobeNewswire
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - MarketScreener
How Oculis Holding Ag (OCS) Affects Rotational Strategy Timing - Stock Traders Daily
Wall Street analysts predict a 106.04% upside in Oculis Holding AG (OCS): Here's what you should know - MSN
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates - sharewise.com
Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6% - MarketBeat
Discipline and Rules-Based Execution in OCS Response - Stock Traders Daily
Assessing Oculis Holding (NasdaqGM:OCS) Valuation After FDA Backing for OCS‑05 and PIONEER Program Progress - simplywall.st
Oculis (NASDAQ:OCS) Shares Down 4.3%Time to Sell? - MarketBeat
Net current asset value per share of Oculis Holding AG – FWB:CR5 - TradingView — Track All Markets
Cash per share of Oculis Holding AG Warrants 2023-06.03.28 on OCULIS HOLDING – NASDAQ:OCSAW - TradingView — Track All Markets
Why analysts upgrade Oculis Holding AG Equity Warrant stock2025 Buyback Activity & Safe Entry Zone Tips - Улправда
Advancing Privosegtor Toward PIONEER Registrational Trials Could Be A Game Changer For Oculis (OCS) - simplywall.st
Is Oculis Holding AG (CR5) stock cheap vs fundamentalsQuarterly Market Summary & Daily Technical Forecast Reports - Улправда
Can Oculis Holding AG stock deliver surprise earnings beatMarket Activity Recap & AI Based Buy/Sell Signal Reports - Улправда
How Oculis Holding AG Equity Warrant stock reacts to inflationary pressuresMarket Rally & Low Risk Growth Stock Ideas - Улправда
Take Profit: How Oculis Holding AG Equity Warrant stock benefits from tech adoptionWeekly Market Outlook & Daily Technical Forecast Reports - Улправда
Oculis (NASDAQ:OCS) Given New $40.00 Price Target at Stifel Nicolaus - Defense World
Oculis (NASDAQ:OCS) Now Covered by JPMorgan Chase & Co. - Defense World
Oculis (NASDAQ:OCS) Shares Gap Up on Analyst Upgrade - Defense World
What sentiment indicators say about Oculis Holding AG stock2025 Volume Leaders & Momentum Based Trading Ideas - Улправда
Oculis stock price target raised to $40 by Stifel on neuro-ophthalmology progress - Investing.com South Africa
Stifel Maintains Oculis Holding (OCS) Buy Recommendation - Nasdaq
Can Oculis Holding AG stock sustain revenue growthDividend Hike & Growth Focused Entry Point Reports - Улправда
Will Oculis Holding AG stock rally after Fed decisionsWeekly Trend Recap & Consistent Income Trade Ideas - Улправда
Oculis (NASDAQ:OCS) Shares Gap Up After Analyst Upgrade - MarketBeat
0.80%
4.56%
자본화:
|
볼륨(24시간):